Retatrutide
Also known as: Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)
Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).
Who's worth your money for Retatrutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 27 scored sellers
$1512 · 480mg · 99.9% purity
Best value
Lowest $/mg among scored sellers
$625 · 1000mg · 100.0% purity
Most tested
61 independent COAs on file
$404 · 150mg · 99.8% purity
Average price
$6.24/mg
Sellers
51
45-day trend
+4.2%
43 of 51 sellers have a current price· 6 stale hidden· 10 unverified hidden
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · 1h ago
$3.15/mg -49.6% vs avg$1512
480mg
- 🇺🇸 Hydro Research Peptides97
via Disclosed Labs · 1h ago
$8.83/mg +41.5% vs avg$530
60mg
- 🇺🇸 Prime Peptides96
via Disclosed Labs · 1h ago
$5.42/mg -13.3% vs avg$325
60mg
- 🇺🇸 Sunrise Bioresearch95
via Disclosed Labs · 1h ago
$0.63/mg -90% vs avg$625
1000mg
- 🇺🇸 Reta One Labs95
via Disclosed Labs · 1h ago
$2.69/mg -56.9% vs avg$404
150mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 1h ago
$4.18/mg -33% vs avg$251
60mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 1h ago
$5.56/mg -11% vs avg$200
36mg
- 🇺🇸 Forge Performance Co.94
via Disclosed Labs · 1h ago
$5.33/mg -14.6% vs avg$160
30mg
- Nova Peptides94
via Disclosed Labs · 1h ago
$6.50/mg +4.1% vs avg$325
50mg
no purity - 🇺🇸 Ignite Peptides93
via Disclosed Labs · 1h ago
$6.00/mg -3.9% vs avg$120
20mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Retatrutide
Get one email when the market actually moves — no newsletter, no noise.
About Retatrutide
CAS
2381089-83-2
Molecular formula
C221H342N46O68
Sequence
YXQGTFTSDYSIXLDKKAQXAFIEYLLEGGPSSGAPPPS
Typical dose range
0.5–12 mg once weekly subcutaneous (Phase 2 titration; 2–8 mg most studied maintenance range)
Half-life
~6 days
COAs for Retatrutide
551 third-party tests across 55 vendors. Each card links to the full report.
For
Retatrutide
by CertaPeptides· batch CP-2607-RET10
For
Retatrutide
by CertaPeptides· batch CP-2608-RET20
For
Retatrutide
by CertaPeptides· batch CP-2608-RET5
For
Retatrutide
by Peptide Partners· batch PX-L916
For
Retatrutide
by Arctic Lab supply· batch RT-2502-B
For
Retatrutide
by VoriLabs· batch RET-2608-B
For
Retatrutide
by VoriLabs· batch RET-2608-E
For
Retatrutide
by VoriLabs· batch RET-2608-F
For
Retatrutide
by jdbioworks· batch 2026-003
For
Retatrutide
by Reta One Labs· batch RT120826
For
Retatrutide
by Sunrise Bioresearch· batch GLP320JUL26-01
For
Retatrutide
by NovaForge Labs· batch LOT-2026-0521
For
Retatrutide
by NovaForge Labs· batch LOT - RT - QSCT1
For
Retatrutide
by Synthesis Peptides· batch 3GR10926
For
Retatrutide
by NovaForge Labs· batch LOT-RT-QSCO1
For
Retatrutide
by Arctic Lab supply· batch RT-2502-A
For
Retatrutide
by NovaForge Labs· batch 2026-ZGT-01
For
Retatrutide
by Reta One Labs· batch RT150826
For
Retatrutide
by CertaPeptides· batch CP-2607-RET30
For
Retatrutide
by CertaPeptides· batch CP-2606-RET50
For
Retatrutide
by Velora Biolabs· batch VBL-RT20-1
For
Retatrutide
by Velora Biolabs· batch VBL-RT15-1
For
Retatrutide
by Velora Biolabs· batch VBL-RT10-1
For
Retatrutide
by Velora Biolabs· batch VBL-RT30-1
23 citations indexed for Retatrutide
Study · 2026
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis
Rationale Retatrutide (LY3437943) is a novel long-acting triple incretin receptor agonist that targets the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR).
rct · 2026
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
Background Retatrutide is an agonist of GIP, GLP-1, and glucagon receptors, and is currently under investigation for the treatment of obesity, type 2 diabetes, and other comorbidities, including knee osteoarthritis and obstructive sleep apnoea.
Study · 2026
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Background Retatrutide is a triple-receptor agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.
case-report · 2026
Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide
A woman in her mid-20s presented with 5 days of persistent nausea, repeated vomiting, loose stools and markedly reduced oral intake. Blood tests, urinalysis, abdominal ultrasonography and cerebral MRI identified no alternative cause.
case-report · 2026
Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis
Growing public interest in incretin-based therapies for weight loss has been accompanied by increasing availability of research peptides purchasable online. Products may be used without medical assessment or counselling regarding adverse effects, sick-day management or appropriate follow-up.
rct · 2026
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes
Aims To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D).